<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Hemostasis and Related Disorders | Fundamentals of Pathology</title>
    
<!-- Preconnect for performance -->
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>

<!-- Google Fonts -->
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">

<!-- Main Stylesheet -->
<link rel="stylesheet" href="../styles/main.css">

<!-- MathJax Configuration -->
<script>
MathJax = {
    tex: {
        inlineMath: [['$', '$'], ['\\(', '\\)']],
        displayMath: [['$$', '$$'], ['\\[', '\\]']],
        processEscapes: true,
        processEnvironments: true,
        tags: 'ams'
    },
    svg: { fontCache: 'global' },
    options: {
        skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
    }
};
</script>
<script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>



  <!-- Reading Progress Bar -->
<div class="reading-progress-container" aria-hidden="true">
    <div class="reading-progress-bar" id="reading-progress"></div>
</div>

<!-- Theme Toggle -->
<button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode" title="Toggle dark mode">
    <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
    <span class="theme-toggle-icon dark-icon">üåô</span>
</button>

<div class="page-wrapper">
    <!-- Floating Mini-TOC -->
    <aside class="floating-toc" id="floating-toc" aria-label="On this page">
        <div class="floating-toc-header">
            <span class="floating-toc-icon">üìë</span>
            <span>On this page</span>
        </div>
        <nav class="floating-toc-nav">
            <ul class="floating-toc-list">
                <!-- Populated by JS -->
            </ul>
        </nav>
    </aside>

    <div class="container">
        <article class="document-article" role="main" id="main-content">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document navigation">
                <div class="nav-container">
                    <a href="../index.html" class="nav-button nav-button--toc" aria-label="Table of Contents">
                        <span class="nav-icon">üìö</span>
                        <span class="nav-text">Contents</span>
                    </a>
                    
                    <a href="chapter-03-neoplasia.html" class="nav-button nav-button--prev" aria-label="Previous section">
                        <span class="nav-icon">‚Üê</span>
                        <span class="nav-text">Previous</span>
                    </a>
                    
                    <div class="document-progress">
                        <div class="progress-indicator">
                            <span class="progress-current">4</span>
                            <span class="progress-separator">/</span>
                            <span class="progress-total">19</span>
                        </div>
                        <div class="progress-bar-container" aria-hidden="true">
                            <div class="progress-bar-fill" style="width: 20%;"></div>
                        </div>
                        <span class="progress-label">Hemostasis and Related Disorders</span>
                    </div>
                    
                    <a href="chapter-05-rbc-disorders.html" class="nav-button nav-button--next" aria-label="Next section">
                        <span class="nav-text">Next</span>
                        <span class="nav-icon">‚Üí</span>
                    </a>
                </div>
            </nav>

            <!-- Breadcrumb -->
            <nav class="breadcrumb" aria-label="Breadcrumb">
                <ol class="breadcrumb-list">
                    <li class="breadcrumb-item"><a href="../index.html">Home</a></li>
                    <li class="breadcrumb-item active" aria-current="page">Chapter 4</li>
                </ol>
            </nav>

            <!-- Document Header -->
            <header class="document-header">
                <div class="header-badge">
                    <span class="badge-icon">ü©∏</span>
                    <span class="badge-text">Hematology</span>
                </div>
                <h1 class="document-title">Hemostasis and Related Disorders</h1>
                <div class="title-meta">
                    <span class="meta-item">
                        <span class="meta-icon">üìÑ</span>
                        <span>Chapter 4</span>
                    </span>
                </div>
            </header>

            <!-- Main Content Area -->
            <div class="content-wrapper">
                
                <!-- Introduction Section -->
                <section id="introduction" class="content-section">
                    <h2 class="section-title">Introduction</h2>
                    
                    <div class="content-card">
                        <h3 id="basic-principles">I. Hemostasis</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Integrity of the blood vessel is necessary to carry blood to tissues.</p>
                                    <ol>
                                        <li>Damage to the wall is repaired by hemostasis, which involves formation of a thrombus (clot) at the site of vessel injury.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Hemostasis occurs in two stages: primary and secondary.</p>
                                    <ol>
                                        <li>Primary hemostasis forms a weak platelet plug and is mediated by interaction between platelets and the vessel wall.</li>
                                        <li>Secondary hemostasis stabilizes the platelet plug and is mediated by the coagulation cascade.</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>
                </section>

                <!-- Primary Hemostasis Section -->
                <section id="primary-hemostasis" class="content-section">
                    <h2 class="section-title">Primary Hemostasis and Related Bleeding Disorders</h2>

                    <div class="content-card">
                        <h3 id="primary-hemostasis-steps">I. Primary Hemostasis</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <strong>Step 1‚ÄîTransient vasoconstriction of damaged vessel</strong>
                                    <ol>
                                        <li>Mediated by reflex neural stimulation and endothelin release from endothelial cells</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <strong>Step 2‚ÄîPlatelet adhesion to the surface of disrupted vessel</strong>
                                    <ol>
                                        <li>Von Willebrand factor (vWF) binds exposed subendothelial collagen.</li>
                                        <li>Platelets bind vWF using the GPIb receptor.</li>
                                        <li>vWF is derived from the Weibel-Palade bodies of endothelial cells and $\alpha$-granules of platelets.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <strong>Step 3‚ÄîPlatelet degranulation</strong>
                                    <ol>
                                        <li>Adhesion induces shape change in platelets and degranulation with release of multiple mediators.
                                            <ol type="i">
                                                <li>ADP is released from platelet dense granules; promotes exposure of GPIIb/IIIa receptor on platelets.</li>
                                                <li>$TXA_2$ is synthesized by platelet cyclooxygenase (COX) and released; promotes platelet aggregation</li>
                                            </ol>
                                        </li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">
                                    <strong>Step 4‚ÄîPlatelet aggregation</strong>
                                    <ol>
                                        <li>Platelets aggregate at the site of injury via GPIIb/IIIa using fibrinogen (from plasma) as a linking molecule; results in formation of platelet plug</li>
                                        <li>Platelet plug is weak; coagulation cascade (secondary hemostasis) stabilizes it.</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="primary-disorders">II. Disorders of Primary Hemostasis</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Usually due to abnormalities in platelets; divided into quantitative or qualitative disorders</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Clinical features include mucosal and skin bleeding.</p>
                                    <ol>
                                        <li>Symptoms of mucosal bleeding include epistaxis (most common overall symptom), hemoptysis, GI bleeding, hematuria, and menorrhagia. Intracranial bleeding occurs with severe thrombocytopenia.</li>
                                        <li>Symptoms of skin bleeding include petechiae ($1-2 \text{ mm}$, Fig. 4.1), purpura ($>3 \text{ mm}$), ecchymoses ($>1 \text{ cm}$), and easy bruising; petechiae are a sign of thrombocytopenia and are not usually seen with qualitative disorders.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>Useful laboratory studies include</p>
                                    <ol>
                                        <li>Platelet count‚Äînormal $150-400 \text{ K}/\mu\text{L}$; $<50 \text{ K}/\mu\text{L}$ leads to symptoms.</li>
                                        <li>Bleeding time‚Äînormal 2-7 minutes; prolonged with quantitative and qualitative platelet disorders</li>
                                        <li>Blood smear‚Äîused to assess number and size of platelets</li>
                                        <li>Bone marrow biopsy‚Äîused to assess megakaryocytes, which produce platelets</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="itp">III. Immune Thrombocytopenic Purpura (ITP)</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Autoimmune production of IgG against platelet antigens (e.g., GPIIb/IIIa)</p>
                                    <ol>
                                        <li>Most common cause of thrombocytopenia in children and adults</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Autoantibodies are produced by plasma cells in the spleen.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">Antibody-bound platelets are consumed by splenic macrophages, resulting in thrombocytopenia.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">
                                    <p>Divided into acute and chronic forms</p>
                                    <ol>
                                        <li>Acute form arises in children weeks after a viral infection or immunization; self-limited, usually resolving within weeks of presentation</li>
                                        <li>Chronic form arises in adults, usually women of childbearing age. May be primary or secondary (e.g., SLE). May cause short-lived thrombocytopenia in offspring since antiplatelet IgG can cross the placenta.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">E</span>
                                <div class="list-content">
                                    <p>Laboratory findings include</p>
                                    <ol>
                                        <li>$\downarrow$ platelet count, often $<50 \text{ K}/\mu\text{L}$</li>
                                        <li>Normal PT/PTT‚ÄîCoagulation factors are not affected.</li>
                                        <li>$\uparrow$ megakaryocytes on bone marrow biopsy</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">F</span>
                                <div class="list-content">
                                    <p>Initial treatment is corticosteroids. Children respond well; adults may show early response, but often relapse.</p>
                                    <ol>
                                        <li>IVIG is used to raise the platelet count in symptomatic bleeding, but its effect is short-lived.</li>
                                        <li>Splenectomy eliminates the primary source of antibody and the site of platelet destruction (performed in refractory cases).</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="microangiopathic-anemia">IV. Microangiopathic Hemolytic Anemia</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Pathologic formation of platelet microthrombi in small vessels</p>
                                    <ol>
                                        <li>Platelets are consumed in the formation of microthrombi.</li>
                                        <li>RBCs are "sheared" as they cross microthrombi, resulting in hemolytic anemia with schistocytes (Fig. 4.2).</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Seen in thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS)</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>TTP is due to decreased ADAMTS13, an enzyme that normally cleaves vWF multimers into smaller monomers for eventual degradation.</p>
                                    <ol>
                                        <li>Large, uncleaved multimers lead to abnormal platelet adhesion, resulting in microthrombi.</li>
                                        <li>Decreased ADAMTS13 is usually due to an acquired autoantibody; most commonly seen in adult females</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">
                                    <p>HUS is due to endothelial damage by drugs or infection.</p>
                                    <ol>
                                        <li>Classically seen in children with <em>E coli</em> O157:H7 dysentery, which results from exposure to undercooked beef</li>
                                        <li><em>E coli</em> verotoxin damages endothelial cells resulting in platelet microthrombi.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">E</span>
                                <div class="list-content">
                                    <p>Clinical findings (HUS and TTP) include</p>
                                    <ol>
                                        <li>Skin and mucosal bleeding</li>
                                        <li>Microangiopathic hemolytic anemia</li>
                                        <li>Fever</li>
                                        <li>Renal insufficiency (more common in HUS)‚ÄîThrombi involve vessels of the kidney.</li>
                                        <li>CNS abnormalities (more common in TTP)‚ÄîThrombi involve vessels of the CNS.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">F</span>
                                <div class="list-content">
                                    <p>Laboratory findings include</p>
                                    <ol>
                                        <li>Thrombocytopenia with $\uparrow$ bleeding time</li>
                                        <li>Normal PT/PTT (coagulation cascade is not activated)</li>
                                        <li>Anemia with schistocytes</li>
                                        <li>$\uparrow$ megakaryocytes on bone marrow biopsy</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">G</span>
                                <div class="list-content">Treatment involves plasmapheresis and corticosteroids, particularly in TTP.</div>
                            </li>
                        </ul>

                        <!-- Fig 4.1 & 4.2 -->
                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-a244de28.jpeg" 
                                     alt="Petechiae on skin and Schistocyte on blood smear" 
                                     class="figure-image"
                                     loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 4.1 Petechiae involving skin. Fig. 4.2 Schistocyte.</figcaption>
                        </figure>
                    </div>

                    <div class="content-card">
                        <h3 id="qualitative-disorders">V. Qualitative Platelet Disorders</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Bernard-Soulier syndrome is due to a genetic GPIb deficiency; platelet adhesion is impaired.</p>
                                    <ol>
                                        <li>Blood smear shows mild thrombocytopenia with enlarged platelets.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Glanzmann thrombasthenia is due to a genetic GPIIb/IIIa deficiency; platelet aggregation is impaired.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">Aspirin irreversibly inactivates cyclooxygenase; lack of $TXA_2$ impairs aggregation.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">Uremia disrupts platelet function; both adhesion and aggregation are impaired.</div>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: Primary Hemostasis -->

                <!-- Secondary Hemostasis Section -->
                <section id="secondary-hemostasis" class="content-section">
                    <h2 class="section-title">Secondary Hemostasis and Related Disorders</h2>

                    <div class="content-card">
                        <h3 id="secondary-principles">I. Secondary Hemostasis</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Stabilizes the weak platelet plug via the coagulation cascade</p>
                                    <ol>
                                        <li>Coagulation cascade generates thrombin, which converts fibrinogen in the platelet plug to fibrin.</li>
                                        <li>Fibrin is then cross-linked, yielding a stable platelet-fibrin thrombus.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Factors of the coagulation cascade are produced by the liver in an inactive state. Activation requires</p>
                                    <ol>
                                        <li>Exposure to an activating substance
                                            <ol type="i">
                                                <li>Tissue thromboplastin activates factor VII (extrinsic pathway).</li>
                                                <li>Subendothelial collagen activates factor XII (intrinsic pathway).</li>
                                            </ol>
                                        </li>
                                        <li>Phospholipid surface of platelets</li>
                                        <li>Calcium (derived from platelet dense granules)</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="secondary-disorders">II. Disorders of Secondary Hemostasis</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Usually due to factor abnormalities</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Clinical features include deep tissue bleeding into muscles and joints (hemarthrosis) and rebleeding after surgical procedures (e.g., circumcision and wisdom tooth extraction).</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>Laboratory studies include</p>
                                    <ol>
                                        <li>Prothrombin time (PT)‚Äîmeasures extrinsic (factor VII) and common (factors II, V, X, and fibrinogen) pathways of the coagulation cascade</li>
                                        <li>Partial thromboplastin time (PTT)‚Äîmeasures intrinsic (factors XII, XI, IX, VIII) and common (factors II, V, X, and fibrinogen) pathways of the coagulation cascade</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="hemophilia-a">III. Hemophilia A</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Genetic factor VIII (FVIII) deficiency</p>
                                    <ol>
                                        <li>X-linked recessive (predominantly affects males)</li>
                                        <li>Can arise from a new mutation (de novo) without any family history</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Presents with deep tissue, joint, and postsurgical bleeding</p>
                                    <ol>
                                        <li>Clinical severity depends on the degree of deficiency.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>Laboratory findings include</p>
                                    <ol>
                                        <li>$\uparrow$ PTT; normal PT</li>
                                        <li>$\downarrow$ FVIII</li>
                                        <li>Normal platelet count and bleeding time</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">Treatment involves recombinant FVIII.</div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="hemophilia-b">IV. Hemophilia B (Christmas Disease)</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Genetic factor IX deficiency</p>
                                    <ol>
                                        <li>Resembles hemophilia A, except FIX levels are decreased instead of FVIII</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="factor-inhibitor">V. Coagulation Factor Inhibitor</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Acquired antibody against a coagulation factor resulting in impaired factor function; anti-FVIII is most common.</p>
                                    <ol>
                                        <li>Clinical and lab findings are similar to hemophilia A.</li>
                                        <li>PTT does not correct upon mixing normal plasma with patient's plasma (mixing study) due to inhibitor; PTT does correct in hemophilia A.</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="von-willebrand">VI. Von Willebrand Disease</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Genetic vWF deficiency</p>
                                    <ol>
                                        <li>Most common inherited coagulation disorder</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Multiple subtypes exist, causing quantitative and qualitative defects; the most common type is autosomal dominant with decreased vWF levels.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">Presents with mild mucosal and skin bleeding; low vWF impairs platelet adhesion.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">
                                    <p>Laboratory findings include</p>
                                    <ol>
                                        <li>$\uparrow$ bleeding time</li>
                                        <li>$\uparrow$ PTT; normal PT‚ÄîDecreased FVIII half-life (vWF normally stabilizes FVIII); however, deep tissue, joint, and postsurgical bleeding are usually not seen.</li>
                                        <li>Abnormal ristocetin test‚ÄîRistocetin induces platelet agglutination by causing vWF to bind platelet GPIb; lack of vWF $\rightarrow$ impaired agglutination $\rightarrow$ abnormal test.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">E</span>
                                <div class="list-content">Treatment is desmopressin (ADH analog), which increases vWF release from Weibel-Palade bodies of endothelial cells.</div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="vitamin-k-deficiency">VII. Vitamin K Deficiency</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Disrupts function of multiple coagulation factors</p>
                                    <ol>
                                        <li>Vitamin K is activated by epoxide reductase in the liver.</li>
                                        <li>Activated vitamin K gamma carboxylates factors II, VII, IX, X, and proteins C and S; gamma carboxylation is necessary for factor function.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Deficiency occurs in</p>
                                    <ol>
                                        <li>Newborns‚Äîdue to lack of GI colonization by bacteria that normally synthesize vitamin K; vitamin K injection is given prophylactically to all newborns at birth to prevent hemorrhagic disease of the newborn.</li>
                                        <li>Long-term antibiotic therapy‚Äîdisrupts vitamin K-producing bacteria in the GI tract</li>
                                        <li>Malabsorption‚Äîleads to deficiency of fat-soluble vitamins, including vitamin K</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="other-secondary-disorders">VIII. Other Causes of Abnormal Secondary Hemostasis</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Liver failure‚Äîdecreased production of coagulation factors and decreased activation of vitamin K by epoxide reductase; effect of liver failure on coagulation is followed using PT.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Large-volume transfusion‚Äîdilutes coagulation factors, resulting in a relative deficiency</div>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: Secondary Hemostasis -->

                <!-- Other Disorders of Hemostasis -->
                <section id="other-hemostasis" class="content-section">
                    <h2 class="section-title">Other Disorders of Hemostasis</h2>

                    <div class="content-card">
                        <h3 id="heparin-induced-thrombocytopenia">I. Heparin-Induced Thrombocytopenia</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Platelet destruction that arises secondary to heparin therapy</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Fragments of destroyed platelets may activate remaining platelets, leading to thrombosis.</div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="dic">II. Disseminated Intravascular Coagulation (DIC)</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Pathologic activation of the coagulation cascade</p>
                                    <ol>
                                        <li>Widespread microthrombi result in ischemia and infarction.</li>
                                        <li>Consumption of platelets and factors results in bleeding, especially from IV sites and mucosal surfaces (bleeding from body orifices).</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Almost always secondary to another disease process</p>
                                    <ol>
                                        <li>Obstetric complications‚ÄîTissue thromboplastin in the amniotic fluid activates coagulation.</li>
                                        <li>Sepsis (especially with <em>E Coli</em> or <em>N meningitidis</em>)‚ÄîEndotoxins from the bacterial wall and cytokines (e.g., TNF and IL-1) induce endothelial cells to make tissue factor.</li>
                                        <li>Adenocarcinoma‚ÄîMucin activates coagulation.</li>
                                        <li>Acute promyelocytic leukemia‚ÄîPrimary granules activate coagulation.</li>
                                        <li>Rattlesnake bite‚ÄîVenom activates coagulation.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>Laboratory findings include</p>
                                    <ol>
                                        <li>$\downarrow$ platelet count</li>
                                        <li>$\uparrow$ PT/PTT</li>
                                        <li>$\downarrow$ fibrinogen</li>
                                        <li>Microangiopathic hemolytic anemia</li>
                                        <li>Elevated fibrin split products, particularly D-dimer
                                            <ol type="i">
                                                <li>Elevated D-dimer is the best screening test for DIC.</li>
                                                <li>Derived from splitting of cross-linked fibrin; D-dimer is not produced from splitting of fibrinogen.</li>
                                            </ol>
                                        </li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">Treatment involves addressing the underlying cause and transfusing blood products and cryoprecipitate (contains coagulation factors), as necessary.</div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="fibrinolysis-disorders">III. Disorders of Fibrinolysis</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Normal fibrinolysis removes thrombus after damaged vessel heals.</p>
                                    <ol>
                                        <li>Tissue plasminogen activator (tPA) converts plasminogen to plasmin.</li>
                                        <li>Plasmin cleaves fibrin and serum fibrinogen, destroys coagulation factors, and blocks platelet aggregation.</li>
                                        <li>$\alpha 2$-antiplasmin inactivates plasmin.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Disorders of fibrinolysis are due to plasmin overactivity resulting in excessive cleavage of serum fibrinogen. Examples include</p>
                                    <ol>
                                        <li>Radical prostatectomy‚ÄîRelease of urokinase activates plasmin.</li>
                                        <li>Cirrhosis of liver‚Äîreduced production of $\alpha 2$-antiplasmin</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">Presents with increased bleeding (resembles DIC)</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">
                                    <p>Laboratory findings include</p>
                                    <ol>
                                        <li>$\uparrow$ PT/PTT‚ÄîPlasmin destroys coagulation factors.</li>
                                        <li>$\uparrow$ bleeding time with normal platelet count‚ÄîPlasmin blocks platelet aggregation.</li>
                                        <li>Increased fibrinogen split products without D-dimers‚ÄîSerum fibrinogen is lysed; however, D-dimers are not formed because fibrin thrombi are absent.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">E</span>
                                <div class="list-content">Treatment is aminocaproic acid, which blocks activation of plasminogen.</div>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: Other Disorders -->

                <!-- Thrombosis Section -->
                <section id="thrombosis" class="content-section">
                    <h2 class="section-title">Thrombosis</h2>

                    <div class="content-card">
                        <h3 id="thrombosis-principles">I. Basic Principles</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Pathologic formation of an intravascular blood clot (thrombus)</p>
                                    <ol>
                                        <li>Can occur in an artery or vein</li>
                                        <li>Most common location is the deep veins (DVT) of the leg below the knee.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Characterized by (1) lines of Zahn (alternating layers of platelets/fibrin and RBCs, Fig. 4.3) and (2) attachment to vessel wall</p>
                                    <ol>
                                        <li>Both features distinguish thrombus from postmortem clot.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">Three major risk factors for thrombosis are disruption in blood flow, endothelial cell damage, and hypercoagulable state (Virchow triad).</div>
                            </li>
                        </ul>

                        <!-- Fig 4.3 -->
                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-9ed8fa5f.jpeg" 
                                     alt="Lines of Zahn in a thrombus" 
                                     class="figure-image"
                                     loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 4.3 Lines of Zahn characterized by alternating layers of platelets/fibrin and RBCs.</figcaption>
                        </figure>
                    </div>

                    <div class="content-card">
                        <h3 id="blood-flow-disruption">II. Disruption in Normal Blood Flow</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Stasis and turbulence of blood flow increases risk for thrombosis.</p>
                                    <ol>
                                        <li>Blood flow is normally continuous and laminar; keeps platelets and factors dispersed and inactivated</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Examples include</p>
                                    <ol>
                                        <li>Immobilization‚Äîincreased risk for deep venous thrombosis</li>
                                        <li>Cardiac wall dysfunction (e.g., arrhythmia or myocardial infarction)</li>
                                        <li>Aneurysm</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="endothelial-damage">III. Endothelial Cell Damage</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Endothelial damage disrupts the protective function of endothelial cells, increasing the risk for thrombosis.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Endothelial cells prevent thrombosis by several mechanisms.</p>
                                    <ol>
                                        <li>Block exposure to subendothelial collagen and underlying tissue factor</li>
                                        <li>Produce prostacyclin ($PGI_2$) and NO‚Äîvasodilation and inhibition of platelet aggregation</li>
                                        <li>Secrete heparin-like molecules‚Äîaugment antithrombin III (ATIII), which inactivates thrombin and coagulation factors</li>
                                        <li>Secrete tissue plasminogen activator (tPA)‚Äîconverts plasminogen to plasmin, which (1) cleaves fibrin and serum fibrinogen, (2) destroys coagulation factors, and (3) blocks platelet aggregation</li>
                                        <li>Secrete thrombomodulin‚Äîredirects thrombin to activate protein C, which inactivates factors V and VIII</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>Causes of endothelial cell damage include atherosclerosis, vasculitis, and high levels of homocysteine.</p>
                                    <ol>
                                        <li>Vitamin B12 and folate deficiency result in mildly elevated homocysteine levels, increasing the risk for thrombosis.
                                            <ol type="i">
                                                <li>Folic acid (tetrahydrofolate, THF) circulates as methyl-THF in the serum.</li>
                                                <li>Methyl is transferred to cobalamin (vitamin B12), allowing THF to participate in the synthesis of DNA precursors.</li>
                                                <li>Cobalamin transfers methyl to homocysteine resulting in methionine.</li>
                                                <li>Lack of vitamin B12 or folate leads to decreased conversion of homocysteine to methionine resulting in buildup of homocysteine.</li>
                                            </ol>
                                        </li>
                                        <li>Cystathionine beta synthase (CBS) deficiency results in high homocysteine levels with homocystinuria.
                                            <ol type="i">
                                                <li>CBS converts homocysteine to cystathionine; enzyme deficiency leads to homocysteine buildup.</li>
                                                <li>Characterized by vessel thrombosis, mental retardation, lens dislocation, and long slender fingers.</li>
                                            </ol>
                                        </li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="hypercoagulable-state">IV. Hypercoagulable State</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Due to excessive procoagulant proteins or defective anticoagulant proteins; may be inherited or acquired</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Classic presentation is recurrent DVTs or DVT at a young age.</p>
                                    <ol>
                                        <li>Usually occurs in the deep veins of the leg; other sites include hepatic and cerebral veins.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>Protein C or S deficiency (autosomal dominant) decreases negative feedback on the coagulation cascade.</p>
                                    <ol>
                                        <li>Proteins C and S normally inactivate factors V and VIII.</li>
                                        <li>Increased risk for warfarin skin necrosis
                                            <ol type="i">
                                                <li>Initial stage of warfarin therapy results in a temporary deficiency of proteins C and S (due to shorter half-life) relative to factors II, VII, IX, and X</li>
                                                <li>In preexisting C or S deficiency, a severe deficiency is seen at the onset of warfarin therapy increasing risk for thrombosis, especially in the skin.</li>
                                            </ol>
                                        </li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">
                                    <p>Factor V Leiden is a mutated form of factor V that lacks the cleavage site for deactivation by proteins C and S.</p>
                                    <ol>
                                        <li>Most common inherited cause of hypercoagulable state</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">E</span>
                                <div class="list-content">
                                    <p>Prothrombin 20210A is an inherited point mutation in prothrombin that results in increased gene expression.</p>
                                    <ol>
                                        <li>Increased prothrombin results in increased thrombin, promoting thrombus formation.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">F</span>
                                <div class="list-content">
                                    <p>ATIII deficiency decreases the protective effect of heparin-like molecules produced by the endothelium, increasing the risk for thrombus.</p>
                                    <ol>
                                        <li>Heparin-like molecules normally activate ATIII, which inactivates thrombin and coagulation factors.</li>
                                        <li>In ATIII deficiency, PTT does not rise with standard heparin dosing.
                                            <ol type="i">
                                                <li>Pharmacologic heparin works by binding and activating ATIII.</li>
                                                <li>High doses of heparin activate limited ATIII; coumadin is then given to maintain an anticoagulated state.</li>
                                            </ol>
                                        </li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">G</span>
                                <div class="list-content">
                                    <p>Oral contraceptives are associated with a hypercoagulable state.</p>
                                    <ol>
                                        <li>Estrogen induces increased production of coagulation factors, thereby increasing the risk for thrombosis.</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: Thrombosis -->

                <!-- Embolism Section -->
                <section id="embolism" class="content-section">
                    <h2 class="section-title">Embolism</h2>

                    <div class="content-card">
                        <h3 id="embolism-principles">I. Basic Principles</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Intravascular mass that travels and occludes downstream vessels; symptoms depend on the vessel involved.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Thromboembolus is due to a thrombus that dislodges; most common type of embolus ($>95\%$)</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>Atherosclerotic embolus is due to an atherosclerotic plaque that dislodges.</p>
                                    <ol>
                                        <li>Characterized by the presence of cholesterol clefts in the embolus (Fig. 4.4A)</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">
                                    <p>Fat embolus is associated with bone fractures, particularly long bones, and soft tissue trauma.</p>
                                    <ol>
                                        <li>Develops while fracture is still present or shortly after repair</li>
                                        <li>Characterized by dyspnea (fat, often with bone marrow elements, is seen in pulmonary vessels, Fig. 4.4B) and petechiae on the skin overlying the chest</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">E</span>
                                <div class="list-content">
                                    <p>Gas embolus is classically seen in decompression sickness.</p>
                                    <ol>
                                        <li>Nitrogen gas precipitates out of blood due to rapid ascent by a diver.</li>
                                        <li>Presents with joint and muscle pain ('bends') and respiratory symptoms ('chokes').</li>
                                        <li>Chronic form (Caisson disease) is characterized by multifocal ischemic necrosis of bone.</li>
                                        <li>Gas embolus may also occur during laparoscopic surgery (air is pumped into the abdomen).</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">F</span>
                                <div class="list-content">
                                    <p>Amniotic fluid embolus enters maternal circulation during labor or delivery</p>
                                    <ol>
                                        <li>Presents with shortness of breath, neurologic symptoms, and DIC (due to the thrombogenic nature of amniotic fluid)</li>
                                        <li>Characterized by squamous cells and keratin debris, from fetal skin, in embolus (Fig. 4.4C)</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>

                        <!-- Fig 4.4 -->
                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-2b523b25.jpeg" 
                                     alt="Emboli types: Atherosclerotic, Fat, and Amniotic fluid" 
                                     class="figure-image"
                                     loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 4.4 Emboli. A, Atherosclerotic embolus characterized by cholesterol clefts. B, Fat embolus with bone marrow elements. C, Amniotic fluid embolus with squamous cells and keratin debris from fetal skin. (A, Courtesy of Professor A. Garfia. C, Courtesy of Shakuntala Teas, MD)</figcaption>
                        </figure>
                    </div>

                    <div class="content-card">
                        <h3 id="pulmonary-embolism">II. Pulmonary Embolism (PE)</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Usually due to thromboembolus; the most common source is deep venous thrombus (DVT) of the lower extremity, usually involving the femoral, iliac, or popliteal veins.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Most often clinically silent because (1) the lung has a dual blood supply (via pulmonary and bronchial arteries) and (2) the embolus is usually small (selfresolves)</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>Pulmonary infarction occurs if a large- or medium-sized artery is obstructed in patients with pre-existing cardiopulmonary compromise; only $10\%$ of PEs cause infarction.</p>
                                    <ol>
                                        <li>Presents with shortness of breath, hemoptysis, pleuritic chest pain, and pleural effusion</li>
                                        <li>V/Q lung scan shows mismatch; perfusion is abnormal.</li>
                                        <li>Spiral CT shows a vascular filling defect in the lung.</li>
                                        <li>Lower extremity Doppler ultrasound is useful to detect DVT.</li>
                                        <li>D-dimer is elevated.</li>
                                        <li>Gross examination reveals a hemorrhagic, wedge-shaped infarct.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">Sudden death occurs with a large saddle embolus that blocks both left and right pulmonary arteries or with significant occlusion of a large pulmonary artery (Fig. 4.5); death is due to electromechanical dissociation.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">E</span>
                                <div class="list-content">Pulmonary hypertension may arise with chronic emboli that are reorganized over time.</div>
                            </li>
                        </ul>

                        <!-- Fig 4.5 -->
                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-067cae6e.jpeg" 
                                     alt="Saddle embolus occluding pulmonary artery" 
                                     class="figure-image"
                                     loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 4.5 Saddle embolus involving pulmonary artery. (Courtesy of Yale Rosen, MD)</figcaption>
                        </figure>
                    </div>

                    <div class="content-card">
                        <h3 id="systemic-embolism">III. Systemic Embolism</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Usually due to thromboembolus</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Most commonly arise in the left heart</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">Travel down systemic circulation to occlude flow to organs, most commonly the lower extremities</div>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: Embolism -->

            </div>

            <!-- Bottom Navigation -->
            <nav class="document-nav document-nav--bottom" role="navigation" aria-label="Document navigation">
                <div class="nav-container">
                    <a href="chapter-03-neoplasia.html" class="nav-button nav-button--prev nav-button--large">
                        <span class="nav-icon">‚Üê</span>
                        <div class="nav-content">
                            <span class="nav-label">Previous</span>
                            <span class="nav-title">Principles of Neoplasia</span>
                        </div>
                    </a>
                    
                    <a href="../index.html" class="nav-button nav-button--toc">
                        <span class="nav-icon">üìö</span>
                        <span class="nav-text">All Topics</span>
                    </a>
                    
                    <a href="chapter-05-rbc-disorders.html" class="nav-button nav-button--next nav-button--large">
                        <div class="nav-content">
                            <span class="nav-label">Next</span>
                            <span class="nav-title">Red Blood Cell Disorders</span>
                        </div>
                        <span class="nav-icon">‚Üí</span>
                    </a>
                </div>
            </nav>
        </article>
    </div>
</div>

<!-- Lightbox Modal -->
<div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
    <div class="lightbox-backdrop"></div>
    <div class="lightbox-content">
        <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
        <img class="lightbox-image" src="" alt="">
        <p class="lightbox-caption"></p>
    </div>
</div>

<!-- JavaScript Dependencies -->
<script src="../js/theme.js"></script>
<script src="../js/navigation.js"></script>
<script src="../js/interactions.js"></script>